89 related articles for article (PubMed ID: 24005158)
1. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.
Gutbrodt KL; Schliemann C; Giovannoni L; Frey K; Pabst T; Klapper W; Berdel WE; Neri D
Sci Transl Med; 2013 Sep; 5(201):201ra118. PubMed ID: 24005158
[TBL] [Abstract][Full Text] [Related]
2. Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.
De Luca R; Soltermann A; Pretto F; Pemberton-Ross C; Pellegrini G; Wulhfard S; Neri D
Mol Cancer Ther; 2017 Nov; 16(11):2442-2451. PubMed ID: 28716814
[TBL] [Abstract][Full Text] [Related]
3. Heme Oxygenase 1-Targeted Hybrid Nanoparticle for Chemo- and Immuno-Combination Therapy in Acute Myelogenous Leukemia.
Yong SB; Kim J; Chung JY; Ra S; Kim SS; Kim YH
Adv Sci (Weinh); 2020 Jul; 7(13):2000487. PubMed ID: 32670766
[TBL] [Abstract][Full Text] [Related]
4. Immunotargeting of a recurrent AML-specific neoantigen.
Apavaloaei A; Perreault C
Nat Cancer; 2023 Oct; 4(10):1403-1405. PubMed ID: 37783806
[No Abstract] [Full Text] [Related]
5. Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.
Schliemann C; Gutbrodt KL; Kerkhoff A; Pohlen M; Wiebe S; Silling G; Angenendt L; Kessler T; Mesters RM; Giovannoni L; Schäfers M; Altvater B; Rossig C; Grünewald I; Wardelmann E; Köhler G; Neri D; Stelljes M; Berdel WE
Cancer Immunol Res; 2015 May; 3(5):547-56. PubMed ID: 25672398
[TBL] [Abstract][Full Text] [Related]
6. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.
Hess C; Neri D
Cancer Immunol Immunother; 2015 May; 64(5):635-44. PubMed ID: 25722088
[TBL] [Abstract][Full Text] [Related]
7. Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice.
Gutbrodt KL; Casi G; Neri D
Mol Cancer Ther; 2014 Jul; 13(7):1772-6. PubMed ID: 24759429
[TBL] [Abstract][Full Text] [Related]
8. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.
Catania C; Maur M; Berardi R; Rocca A; Giacomo AM; Spitaleri G; Masini C; Pierantoni C; González-Iglesias R; Zigon G; Tasciotti A; Giovannoni L; Lovato V; Elia G; Menssen HD; Neri D; Cascinu S; Conte PF; Braud Fd
Cell Adh Migr; 2015; 9(1-2):14-21. PubMed ID: 25562532
[TBL] [Abstract][Full Text] [Related]
9. Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.
Börschel N; Schwöppe C; Zerbst C; Angenendt L; Kessler T; Klapper W; Giovannoni L; Elia G; Neri D; Berdel WE; Mesters RM; Schliemann C
Leuk Res; 2015 Jul; 39(7):739-48. PubMed ID: 25934049
[TBL] [Abstract][Full Text] [Related]
10. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.
Tzeng A; Kwan BH; Opel CF; Navaratna T; Wittrup KD
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3320-5. PubMed ID: 25733854
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
12. A chemically defined trifunctional antibody-cytokine-drug conjugate with potent antitumor activity.
List T; Casi G; Neri D
Mol Cancer Ther; 2014 Nov; 13(11):2641-52. PubMed ID: 25205656
[TBL] [Abstract][Full Text] [Related]
13. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
Perrino E; Steiner M; Krall N; Bernardes GJ; Pretto F; Casi G; Neri D
Cancer Res; 2014 May; 74(9):2569-78. PubMed ID: 24520075
[TBL] [Abstract][Full Text] [Related]
14. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
Kolitz JE; George SL; Benson DM; Maharry K; Marcucci G; Vij R; Powell BL; Allen SL; Deangelo DJ; Shea TC; Stock W; Bakan CE; Hars V; Hoke E; Bloomfield CD; Caligiuri MA; Larson RA;
Cancer; 2014 Apr; 120(7):1010-7. PubMed ID: 24382782
[TBL] [Abstract][Full Text] [Related]
15. Optimized tetramer analysis reveals Ly49 promiscuity for MHC ligands.
McFall E; Tu MM; Al-Khattabi N; Tai LH; St-Laurent AS; Tzankova V; Hall CW; Belanger S; Troke AD; Wight A; Mahmoud AB; Zein HS; Rahim MM; Carlyle JR; Makrigiannis AP
J Immunol; 2013 Dec; 191(11):5722-9. PubMed ID: 24154624
[TBL] [Abstract][Full Text] [Related]
16. Editorial overview: Next generation therapeutics: Creating and exploiting the chemistry of large numbers.
Scheuermann J; Neri D
Curr Opin Chem Biol; 2015 Jun; 26():iv-v. PubMed ID: 25890575
[No Abstract] [Full Text] [Related]
17. Noninternalizing targeted cytotoxics for cancer therapy.
Casi G; Neri D
Mol Pharm; 2015 Jun; 12(6):1880-4. PubMed ID: 25738312
[TBL] [Abstract][Full Text] [Related]
18. Targeting carbonic anhydrase IX with small organic ligands.
Wichert M; Krall N
Curr Opin Chem Biol; 2015 Jun; 26():48-54. PubMed ID: 25721398
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
